Reports Q1 revenue $1.12M, consensus $1.2M. “In the first quarter, we made steady progress in the continued adoption and utilization of Senhance and the ISU, as well as the development of the LUNA(TM) Surgical System,” said Anthony Fernando, Asensus Surgical President and CEO. “We also recently announced a potential acquisition by KARL STORZ, which we believe could accelerate our mission to transform the way surgery is performed on a global scale. Looking to the balance of 2024, our team remains focused on goals and milestones for LUNA and the negotiation of a definitive merger agreement with KARL STORZ, which we hope will lead to a completed transaction.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASXC:
- Options Volatility and Implied Earnings Moves Today, May 14, 2024
- Options Volatility and Implied Earnings Moves This Week, May 13 – May 16, 2024
- Is ASXC a Buy, Before Earnings?
- Asensus Surgical, Inc. Schedules First Quarter Financial and Operating Results Conference Call for May 14, 2024
- Asensus Surgical Announces Sendai Tokushukai Hospital in Japan to Initiate Senhance Surgery Program
Questions or Comments about the article? Write to editor@tipranks.com